主页 > 医学动态 >
【drug-news】2009年第二季度及上半年药厂业绩报道
罗氏上半年净收入减少29%
GENEVA -- Pharmaceuticals maker Roche Holding AG on Thursday posted a 29 percent drop in net income for the first six months because of costs related to the takeover of California-based Genentech, but results were boosted by sales of the antiviral Tamiflu in the face of the swine flu pandemic.
Sales of anticancer drugs also fed the profit of 4.1 billion Swiss francs ($3.84 billion), which compares with 5.7 billion francs in the year-earlier period, Roche ( RHHBY.PK - news - people ) said. Excluding exceptional items, net income attributable to Roche shareholders was up 11 percent at 5.2 billion francs ($4.9 billion).
Group sales were up 2 billion to 24 billion francs ($22.5 billion), an increase of 9 percent in Swiss francs).
"I am especially pleased about the excellent progress we've made in integrating Roche and Genentech ( DNA - news - people )," CEO Severin Schwan said. "Work at Genentech's research and early development center in South San Francisco has continued seamlessly with the existing management team."
Schwan said the company would be realizing synergies from the merger sooner than originally anticipated because of the consolidation of the manufacturing network and streamlining administrative functions. Glaxo, Lilly earnings up; Pfizer down
July 22, 2009 — 9:53am ET | By Tracy Staton
Earnings season is in full swing now, with a coterie of Big Pharma putting out their numbers. The strong dollar is weighing on many drugmakers, while others are beating expectations on currency gains.
Pfizer reported lower second-quarter earnings--$2.26 billion or 34 cents per share--due largely to costs associated with its impending takeover of rival Wyeth and the negative impact of an unfavorable exchange rate on sales. Revenue fell 9 percent to $10.98 billion.
GlaxoSmithKline's numbers suffered from generic competition, but the company said it's seeing strength in consumer healthcare and especially in vaccines. Meanwhile, Glaxo ramped up production of its Relenza swine flu therapy, expecting to triple capacity by year's end. Sales grew 14 percent to almost $11 billion on currency effects; without forex, sales would have dropped 2 percent. Profit grew 12 percent to $3.28 billion.
Eli Lilly said profit rose 21 percent to $1.16 billion or $1.06 per share, beating analysts' estimates. Lilly benefited from rising sales of its Cymbalta antidepressant and gains from favorable currency rates. Revenues rose to $5.29 billion. "Most of the surprise in results were because they got a big benefit on the gross margin because of currency," Deutsche Bank analyst Barbara Ryan told Bloomberg. "The focus from here is clearly on Effient and its launch."
Forest Laboratories saw quarterly earnings rise to $262.9 million or 87 cents per share, as strong sales of its drugs for Alzheimer's disease, hypertension and fibromyalgia helped offset declining sales of its antidepressant Lexapro. Revenues came in 4.3 percent higher at $1.008 billion.
Gilead Sciences boosted quarterly profit by 31 percent to $571.4 million on higher sales of its HIV drugs, but some sales went to inventory. Revenues rose 29 percent to $1.65 billion. "These are pretty strong results, a more than 10 percent beat," Morgan Joseph managing director Shiv Kapoor told Reuters. "Gilead's current revenue, Gilead's current HIV franchise continues to be very strong, much stronger than folks' expectation."
Amylin Pharmaceuticals cut its second-quarter loss to $62.4 million, largely on cost reductions taken in recent quarters. The loss included a $11.4 million charge on sales-force job cuts. Revenues dropped 6 percent to $209.4 million as sales of the company's diabetes meds faltered. Bristol, Wyeth turn in strong Q2 results
July 24, 2009 — 11:05am ET | By Tracy Staton
Related Stories
Earnings roundup: BMS to cut $1B more
Merck preps for merger with cost cuts, strategy
Glaxo, Lilly earnings up; Pfizer down
day on the earnings front, with mostly good news all the way around. Wyeth beat forecasts, and so did Bristol-Myers Squibb. Sepracor and Ranbaxy also reported strong results. Here are some details:
In one of the best pharma performances this quarter, Bristol-Myers posted a 29 percent profit jump due to higher sales of several key products, including the blood thinner Plavix. Net income came in at $983 million, or 49 cents per share, up from $764 million, or 38 cents per share, a year earlier. Revenue rose 3.5 percent to $5.4 billion.
Wyeth had second-quarter profit of $1.27 billion, or 94 cents a share, up from $1.12 billion a year ago. Excluding charges of $52 million related to a cost-cutting program and merger expenses, earnings would have been 98 cents a share, beating analyst estimates. Wyeth's sales declined 4.2 percent to $5.7 billion, hurt by unfavorable exchange rates. A bright spot: Sales of the vaccine Prevnar jumped 13 percent to $783 million.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-09-26 18:32
医学,生命科学网